13 results
A Controlled Trial of Erenumab for Episodic Migraine #EBM #Neuro #Erenumab #Migraine #CGRP #VisualAbstract #NEJM
Episodic Migraine #EBM ... #Neuro #Erenumab ... VisualAbstract #NEJM
Cells, Molecules, and Therapies. Shown is a simplified schematic depiction of major cell types within white-matter
#Pathophys #Neuro ... #Pharm #MultipleSclerosis ... DiseaseModifying #Targets #NEJM
Major Clinical Trials and Evidence Summary for Transfusion Thresholds in Critical Care

TRICC - NEJM 1999 -
Care TRICC - NEJM ... - ICU FOCUS - NEJM ... UGIB TRISS - NEJM ... unnecessary and cause harm ... /vmoitra) #EBM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
Decompression Sickness - The physical examination revealed diffuse violaceous skin mottling over his trunk and arms
Clinical #Derm #EM ... #Pneumatosis #CT ... #NEJM
Effect of Tolvaptan on the Estimated Glomerular Filtration Rate (GFR). #EBM #Nephro #Pharm #Tolvaptam #PCKD #PolyCysticKidneyDisease
#EBM #Nephro #Pharm ... PolyCysticKidneyDisease #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
to Trial Group #EBM ... #Neuro #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... #Neuro #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #NEJM
Six Trials of Patent Foramen Ovale Closure for Stroke with Results Published in the Journal. #EBM
#EBM #Neuro #Cardiology ... EvidenceSummary #Table #NEJM